HOSPITAL UNIVERSITARIO RUBER
Departamento
Maastricht University Medical Centre
Maastricht, HolandaPublicaciones en colaboración con investigadores/as de Maastricht University Medical Centre (9)
2023
-
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 2, pp. 198-205
2022
-
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Cancer Treatment Reviews, Vol. 111
2021
-
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer
Cancers, Vol. 13, Núm. 17
-
Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial
JAMA Oncology, Vol. 7, Núm. 4, pp. 573-584
-
Expected medium- And long-term impact of the COVID-19 outbreak in oncology
JCO Global Oncology, Vol. 7, pp. 162-172
2020
-
Oncological care organisation during COVID-19 outbreak
ESMO Open, Vol. 5, Núm. 4
2017
-
Predictors of intramyocardial hemorrhage after reperfused ST-segment elevation myocardial infarction
Journal of the American Heart Association, Vol. 6, Núm. 8
2016
-
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366
-
Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention
Journal of the American College of Cardiology, Vol. 67, Núm. 23, pp. 2705-2715